

Technical Information Report

AAMI TIR26:2000

Ventricular assist and heart replacement systems

AAMI

Association for the
Advancement of Medical
Instrumentation



Documents

Document Sharing Hub

Ventricular assist and heart replacement systems

Approved 16 October 2000
Association for the Advancement of Medical Instrumentation

Abstract: Provides guidance for gathering data and information to demonstrate the safety and effectiveness of ventricular assist and heart replacement systems for patients with heart dysfunction.

Keywords: electromedical device, ventricular assist device, artificial heart, implants

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that although both standards and TIRs are periodically reviewed, a standard must be acted upon—reaffirmed, revised, or withdrawn—and the action formally approved usually every 5 years but at least every 10 years. For a TIR, AAMI consults with a technical committee about 5 years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI technical information report may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Dept., 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795.

Published by

Association for the Advancement of Medical Instrumentation
1110 N. Glebe Road, Suite 220
Arlington, VA 22201-4795

© 2001 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI at 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-147-1

Contents

	Page
Committee representation.....	5
Foreword	6
Introduction	7
1 Scope.....	8
2 References	8
3 Definitions and abbreviations.....	9
4 Intended clinical use and indications	12
5 System description	12
5.1 Principle of operation	12
5.2 Design consideration	12
5.3 System configuration	13
5.4 System performance and operating limits.....	13
5.5 Design analysis.....	13
5.6 Risk analysis.....	13
5.7 Human factors.....	13
5.7.1 General	13
5.7.2 Specific human factors considerations	13
6 <i>In vitro</i> design evaluation	13
6.1 <i>In vitro</i> test setup.....	14
6.2 "Worst-case" operating conditions	14
6.3 Fluid dynamics	14
6.4 Software verification and validation	14
6.5 Electrical qualification	14
6.5.1 Electromagnetic compatibility	14
6.5.2 Electrical safety	14
6.6 Power sources	15
6.6.1 Transcutaneous energy transmission systems.....	15
6.6.2 Batteries	15
6.7 Mechanical qualification.....	15
6.7.1 Connections and connectors	15
6.7.1.1 Electrical	15
6.7.1.2 Pneumatic/gas	15
6.7.1.3 Blood/conduits	15
6.7.2 Vascular grafts.....	16
6.7.3 Valves	16
6.7.4 Materials qualification	16
6.8 Biocompatibility	16
6.9 Environmental testing	16
7 <i>In vivo</i> design evaluation	16
7.1 <i>In vivo</i> study plan	17
7.2 <i>In vivo</i> protocol.....	17
7.3 <i>In vivo</i> analysis plan.....	17
8 Reliability	17
9 Clinical trial considerations	18
10 Labeling	19

10.1	General	19
10.2	Instructions for use.....	20
10.2.1	General	20
10.2.2	Contra-indications and associated precautions.....	20
10.2.3	Human factors considerations	21
Annexes		
A	Rationale for the development and provisions of this technical information report.....	22
B	Example environmental testing matrix	23
C	Bibliography	25
Tables		
1—	General labeling guidelines	19
B.1—	Test levels and conditions	23
B.2—	EMC test levels	24

Committee representation

Association for the Advancement of Medical Instrumentation

Mechanical Circulatory Support Systems Committee

This technical information report (TIR) was developed by the Mechanical Circulatory Support Systems Committee of the Association for the Advancement of Medical Instrumentation. Committee approval of the TIR does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Mechanical Circulatory Support Systems Committee** had the following members:

<i>Cochairs:</i>	Robert T.V. Kung John T. Watson
<i>Members:</i>	Edwin F. Bjoro, Quality Assurance/Reliability Consulting Specialist, Fairfax, VA O.H. Frazier, MD, Texas Heart Institute Leonard A.R. Golding, MD, Cleveland Clinic Foundation Robert T.V. Kung, PhD, Abiomed Inc. James Lee, World Heart Corporation William T. Maloney, MD, American Association for Thoracic Surgery Jean E. Rinaldi, U.S. Food and Drug Administration Gerson Rosenberg, PhD, M.S. Hershey Medical Center Rhona B. Shanker, Medical Device Auditing & Consulting Richard G. Smith, Cardiowest Technologies Inc. James J. Thompson, Arrow International Inc. John T. Watson, PhD, NIH, National Heart, Lung, and Blood Institute
<i>Alternates:</i>	Francisco Arabia, MD, Cardiowest Technologies Inc. Alan S. Berson, PhD, NIH, National Heart, Lung, and Blood Institute Jal S. Jassawalla, World Heart Corporation Jeffrey P. Lewis, Arrow International Inc.

NOTE—Participation by federal agency representatives in the development of this TIR does not necessarily constitute endorsement by the federal government or any of its agencies.

Foreword

This technical information report (TIR) was developed by the Mechanical Circulatory Support Systems Committee of the Association for the Advancement of Medical Instrumentation (AAMI) in cooperation with the American Society for Artificial Internal Organs and the Society of Thoracic Surgeons. In addition, representatives of many other medical and technical organizations, as well as representatives of government agencies, contributed to this effort.

This TIR reflects the conscientious efforts of concerned physicians and clinical engineers, in consultation with device manufacturers, to develop a guidance document for those performance levels that could be reasonably achieved as of this writing.

Ventricular assist devices and total artificial hearts require extensive validation information. This document covers the documentation required to evaluate both the pump and the console for these devices. Manufacturers are encouraged to apply this document according to the unique characteristics of their system or component. For example, recommendations may be modified or omitted for appropriate application to a particular system or component if appropriate scientific justification is provided. Although this document was developed to meet the needs of an expanding body of knowledge and is based on current technology, the committee will periodically revise the criteria to keep them current.

Suggestions for improving this TIR are invited. Comments and suggested revisions should be sent to AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795.

Introduction

Heart failure is a major public health problem. According to recent statistics from the American Heart Association, 4.8 million Americans have heart failure, and, in 1996, more than 43,000 Americans died of this disease. The number of new cases is around 400,000 per year (Schocken 1992). Further, heart failure is implicated as a contributing factor in more than 250,000 deaths each year (Yusuf 1992). Overall, hospital admissions for heart failure have increased 10-fold since 1970 (Lorell 1994). Particularly at risk for heart failure are the elderly (≥ 60 years), who account for 70 % of heart failure patients (Haldeman *et al* 1998), and for whom congestive heart failure is the leading cause of hospitalization. Heart failure is the largest diagnosis-related group (DRG) for Medicare payments. However, although the prevalence of heart failure increases with age, almost one-third of patients—1.6 million Americans—contract the disease before the age of 60. The economic costs are enormous; \$21 billion is the estimated U.S. cost for treating this condition (American Heart Association 1999). There is a poor prognosis for the Medicare population; about 17 % of men and 24 % of women survive 6 years after their first hospitalization for heart failure (Croft 1999).

Despite recent developments of pharmacologic agents developed specifically to treat advancing heart failure, the prognosis for 1-year survival for patients with class IV heart failure is between 40 % and 50 % (AHA 2000) and about 25 % at 2 years. For the vast majority of these patients, cardiac replacement therapy in the form of cardiac transplantation is the only viable treatment option. According to recent statistics provided by the United Network for Organ Sharing (UNOS), cardiac transplant patients have an in-hospital mortality of less than 5 %, a 1-year actuarial survival rate approaching 85 %, and 5-year survival rates of greater than 70 %. Yet the success of cardiac transplantation remains limited by the complications of chronic immunosuppressive therapy, by the development of accelerated allograft atherosclerosis, and, most important, by the continuing serious shortage of donor organs. An enormous difference remains between the number of Americans annually who might benefit from cardiac transplantation (~15,000–70,000) versus those who actually receive transplants (2,427 in 1997; UNOS). And, because the number of cardiac transplants is not expected to increase appreciably in the foreseeable future, there is considerable interest in developing new therapies for patients suffering from end-stage heart failure.

The Institute of Medicine evaluated the Artificial Heart Program of the National Heart, Lung, and Blood Institute in 1991 (Hogness 1991). The panel concluded that by the year 2010, there could be an annual pool of 35,000 to 70,000 candidates for mechanical circulatory support or some other form of treatment. Surgical procedures such as left ventriculectomy and myoplasty have not led to clinical benefit in most patients. Xenotransplantation using nonhuman hearts is under active investigation. Areas of concern include immunologic response of the host, inadequate performance of the non-human heart, and the possibility of transferring infectious organisms to the host. These agents sometimes have long incubation periods (10–20 years) as seen with human immunodeficiency virus and acquired immune deficiency syndrome (HIV–AIDS). An additional patient group with acutely failing hearts numbering in the tens to 100,000 annually may benefit from artificial heart therapy.

For the foreseeable future, the need for mechanical circulatory support is well defined and growing. This guidance document is intended to assist research teams and manufacturers in producing highly reliable ventricular assist devices and artificial hearts—at a reasonable cost to society—that will provide a good quality of life for patients with heart failure during their remaining lifetimes.

Ventricular assist and heart replacement systems

1 Scope

This document is intended to be a guideline for gathering data and information to demonstrate the safety and effectiveness of ventricular assist and heart replacement systems for patients with heart dysfunction. Manufacturers are encouraged to apply this document according to the unique characteristics of their system or component. For example, some of the evaluations may be modified or omitted if appropriate scientific justification is provided.

This document identifies the preclinical *in vitro*, *in vivo*, and clinical evaluations that should be performed to meet the requirements of the scope of this document.

NOTE—This technical report is considered “informative,” and use of the terms “shall,” “should,” and so forth should be considered within the context of this technical report only. That is, if the decision is made to use these guidelines, then the guidelines should be followed in adherence with the requirements (“shall”) and recommendations (“should”) as set forth in this technical report.

2 References

The following documents contain provisions that, through reference in this text, constitute provisions of this technical information report (TIR). At the time of publication, the editions indicated were valid. All documents are subject to revision, and parties to agreements based on this Association for the Advancement of Medical Instrumentation (AAMI) TIR are encouraged to investigate the possibility of applying the *most recent editions* of the documents listed below. The Association for the Advancement of Medical Instrumentation maintains a register of currently valid AAMI/American National Standards.

2.1 ASSOCIATION FOR THE ADVANCEMENT OF MEDICAL INSTRUMENTATION (AAMI). *Cardiovascular implants—Vascular graft prostheses*. ANSI/AAMI VP20:1994. Arlington (Vir.): AAMI, 1994. American National Standard.

2.2 ASSOCIATION FOR THE ADVANCEMENT OF MEDICAL INSTRUMENTATION (AAMI). *Biological evaluation of medical devices—Part 1: Evaluation and testing*. ANSI/AAMI/ISO 10993-1:1997. Arlington (Vir.): AAMI, 1997. American National Standard.

2.3 ASSOCIATION FOR THE ADVANCEMENT OF MEDICAL INSTRUMENTATION (AAMI). *Quality systems—Medical devices—Particular requirements for the application of ISO 9001*. ANSI/AAMI/ISO 13485:1996. Arlington (Vir.): AAMI, 1996. American National Standard.

2.4 ASSOCIATION FOR THE ADVANCEMENT OF MEDICAL INSTRUMENTATION (AAMI). *Medical devices—Symbols to be used with medical device labels, labeling, and information to be supplied*. ANSI/AAMI/ISO 15223:2000. Arlington (Vir.): AAMI, 2000. American National Standard.

2.5 AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS (ASAIO). *Long term mechanical circulatory support system reliability recommendation*. ASAIO J. 1998. 44:108–14.

2.6 CODE OF FEDERAL REGULATIONS. *Investigational device exemptions*. 21 CFR Part 812. And *Pre-market approval of medical devices*. 21 CFR Part 814.

2.7 CODE OF FEDERAL REGULATIONS. *Federal Food, Drug, and Cosmetic Act*, as amended in February 1998, and related regulations. 21 CFR Parts 800–899.

2.8 INTERNATIONAL ELECTROTECHNICAL COMMISSION. *Medical electrical equipment. Part 1: General requirements for safety, second edition*. IEC 60601-1:1988. Geneva: IEC, 1988.

2.9 INTERNATIONAL ELECTROTECHNICAL COMMISSION. *Medical electrical equipment, Part 1: General requirements for safety—2. Collateral standard: Electromagnetic compatibility—Requirements and texts*. IEC 60601-1-2:1993. Geneva: IEC, 1993.